Swedish biotech 2A Pharma AB secured a license to use Medigene AG's AAVLP technology to develop vaccine treatments.

The preclinical stage, adeno-associated virus-like particles technology is believed to have the potential to develop vaccines for cancer and infectious diseases.

The technology is unrelated to Medigene's current immunotherapy programs and was a former research project at the company before it focused on T-cell immunotherapy.

Medigene will receive undisclosed milestone payments as well as royalties on sales of future AAVLP products as a result of the agreement.